NewLink Genetics updates enrollment info on Pivotal Phase 3 HyperAcute trial

NewLink Genetics announced that in Q2 of 2012 it passed the midpoint in enrollment in its Phase 3 HyperAcute Pancreas immunotherapy product candidate, or algenpantucel-L, trial as number of participating institutions reached to 74 sites around the U.S. "Now that we have passed the midway point of trial enrollment, we are confident that the trial will be fully enrolled before the end of 2013," said Dr. Nick Vahanian, President and Chief Medical Officer of NewLink Genetics. He added, "We are very thankful for the support we have received from our patients and investigators and based on currently available data we anticipate reaching the trigger event for the first interim analysis in early 2013."